| The company at present has a wholly-owned subsidiary called Indus Biosciences in the city, which is involved in R&D activities. |
| Bhaskar R Venepalli, president of CiVenti Chem LLC, told Business Standard that the work on the new facility at the Jeedimetla Industrial Estate would begin in November and production would begin from 2006. |
| "Apart from carbohydrate derivatives, the new facility would also focus on developing intermediaries and products related to nanotechnology," Venepalli said. |
| CiVenti Chem entered into an agreement with US-based Ferro Corporation to manufacture, market and sell the non-regulated forms of the carbohydrate product line of Ferro Pfanstiehl. |
| According to him, carbohydrates have become crucial intermediates in pharmaceutical, biopharma, vaccine, nutriceutical and diagnostic manufacturing. "The company has targeted the above segments for growth and the tie-up will help," he added. |
| Last year, the company invested Rs 4 crore in building a modern laboratory with 30 fume hoods (which provide safety to minimise chemical exposure to research workers), four walk-in hoods and a kilo lab. "Indus now is well equipped to make gram to multi kilogram scale of complex organic molecules, pharmaceutical intermediates and APIs," he said. |
| Venepalli said that around 90 per cent of the products the company makes go into pharmaceutical and biotechnology industry, which have a potential of becoming a drug in the long run. |
| The challenge of the company, he said, is to satisfy the unmet need for gm to kg quantities of chemical building blocks and pharmaceutical intermediates to support the R&D efforts of its pharmaceutical, agrochemical and biochemical customers. |
| Venepalli said that the company was open to partnering with other companies in the same space to improve on the product line. "We have been approached by various companies but many did not meet the technology and capabilities that we are looking for," he said. |
Explore Business Standard